Elanco Animal Health Inc: management transactions · United States · SEC (Form 4)

About Elanco Animal Health Inc

Elanco Animal Health Inc. is a U.S.-based animal health company listed in the United States on the NYSE/NASDAQ market under ticker ELAN. The company is headquartered in Indianapolis, Indiana, United States. It operates in a defensive, recurring-demand segment of healthcare: preventing and treating disease in companion animals and livestock. For investors, Elanco sits at the intersection of veterinary pharma, food production, and animal welfare, which gives the business exposure to structurally important end markets rather than purely discretionary demand. ([elanco.com](https://elanco.com/en-us/about-us/about-elanco)) Elanco traces its roots back to 1960, when the Elanco brand was created following the reorganization of Eli Lilly and Company’s Agricultural and Industrial Sales Division. The company highlights more than 70 years of history and says it evolved from an internal sales unit into one of the world’s largest independent animal health businesses. Its expansion accelerated through acquisitions and portfolio building, especially after 2007, when it entered a new growth phase in pet health and later added multiple animal health assets between 2010 and 2016. That history is relevant because it explains why Elanco has both legacy livestock capabilities and a broader companion-animal platform today. ([elanco.com](https://www.elanco.com/en-us/about-us/our-history)) Operationally, Elanco’s business is centered on two main segments: Pet Health and Farm Animal. Pet Health covers dogs and cats, with products focused on parasiticides, dermatology, flea and tick control, and other commonly used veterinary solutions. Farm Animal addresses cattle, swine, and poultry, with offerings intended to support herd health, productivity, and disease prevention. The company also provides supporting services and product information for veterinarians, farmers, producers, and pet owners. In simple terms, Elanco sells animal-care solutions that aim to improve animal health outcomes and, in livestock, help protect the food supply chain. ([elanco.com](https://elanco.com/en-us/products-and-services?utm_source=openai)) From a competitive standpoint, Elanco is positioned as a global diversified player with recognized brands, a wide product portfolio, and meaningful exposure to both companion animals and food-producing species. That combination can be attractive because it reduces dependence on a single end market, while also leaving the company exposed to competition from larger animal-health peers, pricing pressure, and regulation. The company’s geographic footprint is international, with commercial and operational activity across North America, Europe, and other key markets. ([elanco.com](https://elanco.com/en-us/about-us/about-elanco)) Recent developments are important for the investment case. In July 2024, Elanco closed the sale of its aqua business to a subsidiary of Merck Animal Health, a move that sharpened the company’s focus on its core pet and farm animal categories. In 2025, Elanco also moved into a new corporate headquarters arrangement in Indianapolis and announced regulatory and commercial progress around Zenrelia, including European approval and U.S. label updates. For French-speaking investors tracking U.S.-listed names, Elanco remains a specialized animal-health platform with a mix of innovation upside, regulatory execution risk, and sector consolidation potential. ([stocklight.com](https://stocklight.com/stocks/us/nyse-elan/elanco-animal-health/annual-reports/nyse-elan-2026-10K-26667808.pdf))